Leipzig University Medical School, Institute for Drug Discovery

 Q: WHAT IS THE FOCUS OF YOUR LAB’S RESEARCH? 

A: The research of the new Institute for Drug Discovery seeks to combine computational and experimental efforts to investigate proteins and their interactions with small molecule substrates. The Medicinal Synthetic Chemistry Core is part of the new institute and responsible for the synthesis of potentially bio-active compounds based on the computational results predicting a high binding affinity to the proteins’ active sites. 

Q: WHAT WAS YOUR PREVIOUS WORKFLOW OR CHALLENGES? 

A: Previously, we separated all unknown by-products of our synthesis in order to investigate their structure based on NMR and external mass spec service. This time wasting workflow often resulted in a dead-end strategy with low efficiency. 

Q: WHY DID YOU INCORPORATE THE expression^® CMS INTO YOUR LABORATORY? 

A: Since the purchase of the CMS, we improved our strategic synthesis planning extraordinarily. By using Plate Express™ as TLC-Interface together with the expression^® CMS, the by-products could become quickly separated on TLC-plates and directly analyzed by mass spectrometry afterwards. Now we see it, now we know it, and we get it quickly purified. 

Q: WHO WOULD YOU RECOMMEND TO PURCHASE THE expression^® CMS? 

A: I will highly recommend the CMS to all research institutes with a strong synthetical and natural product background of small molecules.